K-Ras (G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
K Sakamoto, Y Kamada, T Sameshima… - Biochemical and …, 2017 - Elsevier
Abstract Amino-acid mutations of Gly 12 (eg G12D, G12V, G12C) of V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog (K-Ras), the most promising drug target in cancer therapy,
are major growth drivers in various cancers. Although over 30 years have passed since the
sarcoma viral oncogene homolog (K-Ras), the most promising drug target in cancer therapy,
are major growth drivers in various cancers. Although over 30 years have passed since the
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论